DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • China
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
301201 logo

ChengDa Pharmaceuticals Co., Ltd. Stock Price

SZSE:301201 Community·CN¥5.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

301201 Share Price Performance

CN¥0
-27.22 (-100.00%)
​
CN¥0
-27.22 (-100.00%)
​
Price CN¥0
Thu, 10 Sep 26
Share Pricen/a

301201 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with low risk.

3 Risks
0 Rewards
View Full Analysis

ChengDa Pharmaceuticals Co., Ltd. Key Details

CN¥479.4m

Revenue

CN¥342.7m

Cost of Revenue

CN¥136.7m

Gross Profit

CN¥159.1m

Other Expenses

-CN¥22.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.15
28.51%
-4.68%
2.5%
View Full Analysis

About 301201

Founded
1980
Employees
659
CEO
Gang Lu
WebsiteView website
www.chengdapharm.com

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, musculoskeletal system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates. ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.

Recent 301201 News & Updates

Recent updates

No updates

ChengDa Pharmaceuticals Co., Ltd. Competitors

688506 logo

Sichuan Biokin PharmaceuticalLtd

Symbol: SHSE:688506
Market cap: CN¥99.2b
000538 logo

Yunnan Baiyao GroupLtd

Symbol: SZSE:000538
Market cap: CN¥90.1b
600436 logo

Zhangzhou Pientzehuang Pharmaceutical

Symbol: SHSE:600436
Market cap: CN¥73.5b
300759 logo

Pharmaron Beijing

Symbol: SZSE:300759
Market cap: CN¥70.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide